

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



"Express Mail" mailing label number EL856150745 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on October 15, 2001

By: Printed: Nancy Ramos **IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Bandman, et al.

Title: HUMAN NUCLEOLIN-LIKE PROTEIN

Serial No.: To Be Assigned

Filing Date:

Herewith

Examiner: To Be Assigned

Group Art Unit:

To Be Assigned

---

Box Patent Application  
Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Applicants respectfully submit under 37 C.F.R. 1.98(3)(d) that copies of the references are not included herein as copies were previously cited by or submitted to the Office in parent application Serial No.09/241,333, filed on February 1, 1999, which is a divisional of application Serial No.08/990,114, filed on December 12, 1997, now issued Patent No. 5,932,475, issued August 3, 1999, from which we are claiming priority under 35 U.S.C. 120.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant

and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108. A duplicate copy of this communication is enclosed.**

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: October 15, 2001

Barrie D. Greene  
Barrie D. Greene  
Reg. No. 46,740  
Direct Dial Telephone: (650) 621-7576

3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 845-4166

U.S. Department of Commerce, Patent and Trademark Office				Atty Docket No.		Serial No.	
				PF-0451-2 DIV		To Be Assigned	
LIST OF REFERENCES CITED BY APPLICANTS				Applicants			
(Use several sheets if necessary)				Bandman et al.			
				Filing Date		Group	
				Herewith		To Be Assigned	
U.S. Patent Documents							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
Foreign Patent Documents							
		Document	Date	Country	Class	Subclass	Trans Yes
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	1	Lapeyre, B. et al., "Nucleolin, the major nucleolar protein of growing eukaryotic cells: An unusual protein structure revealed by the nucleotide sequence", <u>Proc. Natl. Acad. Sci. USA</u> , 84: 1472-1476 (1987)					
	2	Erard, M.S. et al., "A major nucleolar protein, nucleolin, induces chromatin decondensation by binding to histone H1", <u>Eur. J. Biochem.</u> , 175: 525-530 (1988)					
	3	Deng, J.S. et al., "Internalization of anti-nucleolin antibody into viable HEp-2 cells", <u>Mol. Biol. Rep.</u> , 23: 191-195 (1996)					
	4	Bell, S.A. et al., "Specificity of antinuclear antibodies in scleroderma-like chronic graft-versus-host disease: clinical correlation and histocompatibility locus antigen association", <u>Br. J. Dermatol.</u> , 134: 848-854 (1996)					
	5	Zaidi, S.H.E. and J.S. Malter, "Nucleolin and Heterogeneous Nuclear Ribonucleoprotein C Proteins Specifically Interact with the 3'-Untranslated Region of Amyloid Protein Precursor mRNA", <u>J. Biol. Chem.</u> , 270: 17292-17298 (1995)					
	6	Lapeyre, B. et al., (Direct Submission), GenBank Sequence Database (Accession 128842), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland, 20894, (GI 128842)					
	7	Bork P., "Powers and pitfalls in sequence analysis: the 70% hurdle", <u>Genome Research</u> , 10: 398-400 (2000)					
Examiner			Date Considered				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.							

U.S. PAT. & TM. OFF.  
 09/29/01  
 10/15/01